Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension

BACKGROUND: Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies. We performed safety and efficacy analyses of this pooled dataset (n = 460). METHODS: Efficacy was...

Descripción completa

Detalles Bibliográficos
Autores principales: Biaggioni, Italo, Arthur Hewitt, L., Rowse, Gerald J., Kaufmann, Horacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427571/
https://www.ncbi.nlm.nih.gov/pubmed/28494751
http://dx.doi.org/10.1186/s12883-017-0867-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427571/
https://www.ncbi.nlm.nih.gov/pubmed/28494751
http://dx.doi.org/10.1186/s12883-017-0867-5

Ejemplares similares